Categories

Tag: Uncategorized

CONSUMERS/QUALITY: LASIK–not as user friendly as it’s supposed to be

There’s been lots of BS about how the price reductions in those ads for LASIK "prove" that cash based consumer payment works in health care. I always thought they were like the teaser prices in travel  adverts in the Sunday papers–only good if you were leaving Tuesday at midnight, staying 4 months, taking no luggage, and having to fly the plane yourself while the pilot takes a nap.

And now HSC shows that it’s not as advertised.

HSC president Paul Ginsburg, Ph.D., points out that current efforts to increase price transparency for health care services often downplay “the complexity of decisions about medical care, patients’ dependence on physicians for guidance about appropriate services, and the need for information on quality.”
Ginsburg cautions that simply giving consumers a price list of “a la carte” services does little to help them make informed choices about which providers will cost less for an episode of care, let alone which providers offer the best value — or the optimal combination of the lowest cost and highest quality.
The article also points out that insured people have different needs for price information than uninsured people. Insured people need to know what their costs will be under their insurance and benefit structure. And policymakers should be careful not to overlook the role of health plans in negotiating better prices and translating complex price and quality data into usable consumer information that can potentially help steer patients to lower-cost, higher-quality providers, the article notes. Researchers chose the LASIK market for in-depth analysis largely because the vision correction surgery is widely regarded as the self-pay market with the most favorable conditions for consumer shopping. LASIK is an elective, nonurgent, simple procedure, giving consumers time and ability to shop; screening exams are not required to obtain initial price quotes, keeping the dollar and time costs of shopping reasonable; and easy entry of providers (ophthalmologists) into the market has stimulated competition and kept prices down.
However, LASIK patients still face significant hurdles when shopping from inconsistent bundling of what’s included in the procedure price to misleading advertising to quality concerns.
— Inconsistent Bundling. The package of services included in LASIK procedure fees varies across providers. For example, one critical factor is whether the cost of enhancement surgery is included in the fee. A price quote that appears to be the best deal but does not include follow-up operations if needed might end up being the highest-price option.
— Misleading Advertising. Misleading offers for free consultations or for LASIK for $299 and promises that LASIK would eliminate the need for glasses and contacts for life have all come under scrutiny by state and federal regulators, resulting in enforcement actions and settlements to halt the misleading practices.
— Quality Issues. Many industry observers expressed concern that LASIK is regarded as a commodity by some consumers, leading them to shop only on price, when provider quality may vary considerably. Even when consumers are interested in obtaining quality information, the study finds that it is not easy; those wishing to compare provider quality must gather information on success and complication rates from each LASIK surgeon’s practice.

Which of course means that if we’re going to get to real consumer purchasing, we need to figure out a rational way to price for rational bundles of service–and we have to make sure that providers are showing apples to apples comparisons.

POLICY: Centrist democratic policy wonks talk shop

The Century Foundation has a discussion from a bunch of health care policy experts/pundits about the latest developments in the health reform “debate”. Given the large cast of characters (inc Aaron, Hacker, Relman and younger punks Cohn, Klein et al), it’s interesting stuff, but not exactly as diverse as say Cato’s recent back and forth! Yup, it’s a bunch of DimmyCrats talking to each other, but smart ones. Here’s the document. (rather annoyingly it’s a PDF).

PHARMA: The Future of Non-Profit Drug Development By Merrill Goozner

Merrill Goozner has been writing about economics and health care for many years. The former chief economics correspondent for the Chicago Tribune, Merrill has written for a long list of publications including the New York Times, The American Prospect and The Washington Post. His most recent book, "The $800 Million Dollar Pill – The Truth Behind the Cost of New Drugs " (University of California Press, 2004) has won acclaim from critics for its treatment of the issues facing the health care system and the pharmaceutical industry in particular. Today he has something to say about a familiar topic : the relationship between public sector R&D investment and innovation in the pharmaceutical and biotech industries. You can read more pieces by Merrill at  Gooznews.com

The United States is the world leader in investing in biomedical
research and development. In the public sector, the National Institutes
of Health spent $28.6 billion in 2005, largely for basic science
research. The pharmaceutical industry spent an estimated $39 billion in
2004. This includes investment in the U.S. by U.S.-based firms,
investment overseas by U.S. firms, and foreign companies’ R&D
expenditures in the U.S. Indeed, over the past quarter century, the
private sector’s investment in the search for new medicines has grown
eight percent per year on average, faster than the industry’s growth in
sales and profits.

Despite this massive public and private effort, output, as measured
by the number of new drugs, biologics, vaccines and devices approved
for use by regulatory bodies like the U.S. Food and Drug
Administration, has slowed in recent years. Last year, the FDA approved
just 21 new drugs and biologics, the second lowest total since 1993.
Moreover, about half of these new drugs were not given priority status
by the FDA, which meant they were not considered a significant new
advance in medicine. This significance ratio has held steady for over a
decade. Clearly, the steady increase in private and public R&D
spending is generating diminishing returns, whether measured by return
on investment or public health.

Continue reading…

INTERNATIONAL: Having run ahead on primary care PCP, Brits copying Medicare on hospital P4P

The Brits have decided that in at least some regions their hospitals are going to try American style P4P

Health bosses have announced a plan to reward hospitals for low death and infection rates and few readmissions. NHS North West said it was piloting a scheme where cash bonuses are paid to hospitals following the success of a similar programme in the US. Trusts will compete for a total pot of £1.5 million, with any ranking in the top 10 per cent or 20 per cent getting a share. Initially, payments will be made for treatments for heart failure, pneumonia, heart bypass grafts, and hip and knee replacements. But critics said people would expect hospitals to be prioritising safe care anyway.

Don’t forget that on the primary care side they’ve been well ahead of anyone else. Although that’s had it’s issues too. The first year the GPs beat their targets so easily, they’ve made lots more money then the government thought they would.

BLOGS/OFF-TOPIC: A Brief History Of Football Violence

Over at Spot-on I’m writing about a not very health care topic A brief history of football violence.


Only a few months after winning the World Cup,
Italian football is in crisis – again. Last year a referee-tampering
scandal sent Series A champions and Italy’s most famous club Juventus
to the barren wastelands of Serie B. Last weekend Italian football was
shut down after a policeman was killed by a crowd in a Series A game in
Sicily.


Currently a 17-year-old is the main suspect. And the government has reacted strongly. Apparently only six stadiums are going to be allowed to reopen
any time soon. The others lack the suddenly required safety features
(including close circuit TV) which they’ve supposed to have had for
several years. This includes Italy’s most famous arena, the San Siro in
Milan which is shared between the two giant Milan clubs, AC and Inter.

Anyone who’s ever seen the briefest scenes of Italian football
on TV will probably have been astonished by the huge fluorescent
purpley-red flares set off by the fans standing behind the goals . They
usually are lit when their team scores, but in some cases they’ve been
used to disrupt games. The most notable case was in the semi-final of
the European Champions League played in San Siro Stadium between the
two Milan clubs. Inter were losing, then had a goal disallowed, and their fans threw flares onto the field. One hit the AC Milan goalkeeper.
The game was halted, then abandoned, and later awarded to AC Milan (who
went on to lose the final to Liverpool). Inter’s penalty was the
proverbial slap on the wrist – they were forced to play their next 4
home games in an empty stadium. Go on, continue

 

assetto corsa mods